We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
118 hedge funds and large institutions have $256M invested in Lyell Immunopharma in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
42% more capital invested
Capital invested by funds: $180M → $256M (+$76.2M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% more funds holding
Funds holding: 106 → 118 (+12)
10% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 30
0.18% more ownership
Funds ownership: 2.44% → 2.62% (+0.18%)
0% more call options, than puts
Call options by funds: $3K | Put options by funds: $3K
Holders
118
Holders Change
+12
Holders Change %
+11.32%
% of All Funds
1.72%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
25
Increased
33
Reduced
30
Closed
13
Calls
$3K
Puts
$3K
Net Calls
–
Net Calls Change
-$11K
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.92M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.68M |
| 3 |
BlackRock
New York
|
+$1.59M |
| 4 |
Morgan Stanley
New York
|
+$1.51M |
| 5 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$1.34M |
